Accelerating FDA Submissions Through AI-Assisted Module Drafting to Reduce Risk & Enhance Regulatory Efficiency

9:00 am - Thursday 6th August 2026

  • Shortening submission timelines and expanding legal and regulatory capacity by embedding AI into FDA module drafting for a live Phase 2 asset
  • Mitigating hallucination, confidentiality, and trade-secret exposure through structured guardrails, validation workflows, and disciplined human oversight
  • Demonstrating measurable ROI through a real-world implementation with an external AI partner while preserving defensibility and data integrity

Speakers:

General Counsel & Corporate Secretary 
Enveda Therapeutics, Inc.